| Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment M Schmitz, P Breithaupt, N Scheidegger, G Cario, L Bonapace, ... Blood, The Journal of the American Society of Hematology 118 (7), 1854-1864, 2011 | 95 | 2011 |
| An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML S Lin, C Larrue, NK Scheidegger, BKA Seong, NV Dharia, M Kuljanin, ... Cancer discovery 12 (2), 432-449, 2022 | 42 | 2022 |
| The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL B Bornhauser, G Cario, A Rinaldi, T Risch, V Rodriguez Martinez, ... Blood advances 4 (17), 4052-4064, 2020 | 8 | 2020 |
| An in vivo CRISPR screening platform for prioritizing therapeutic targets in AML. Cancer Discov. 2022; 12: 432–449. doi: 10.1158/2159-8290 S Lin, C Larrue, NK Scheidegger, BKA Seong, NV Dharia, M Kuljanin, ... CD-20-1851.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 8 | |
| Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia C Larrue, S Mouche, S Lin, F Simonetta, NK Scheidegger, L Poulain, ... Leukemia 37 (4), 765-775, 2023 | 6 | 2023 |
| Combining menin and MEK inhibition to target poor prognostic KMT2A-rearranged RAS pathway-mutant acute leukemia N Scheidegger, G Alexe, D Khalid, RE Ries, J Wang, TA Alonzo, J Perry, ... Blood 142, 166, 2023 | 1 | 2023 |
| SLC5A3 Transports Myo-Inositol to Support the Growth of Acute Myeloid Leukemia S Lin, NK Scheidegger, G Alexe, BKA Seong, NV Dharia, C Wechsler, ... Blood 138, 3319, 2021 | 1 | 2021 |
| P410: COMBINING MENIN AND MEK INHIBITION TO TREAT CHILDREN WITH POOR PROGNOSTIC KMT2A-R RAS-MUTANT ACUTE LEUKEMIA N Scheidegger, G Alexe, D Khalid, J Perry, S Armstrong, Y Pikman, ... HemaSphere 7 (S3), e0491723, 2023 | | 2023 |
| The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL (vol 4, pg 4052, 2020) B Bornhauser, G Cario, A Rinaldi, T Risch, VR Martinez, M Schuette, ... BLOOD ADVANCES 6 (8), 2700-2700, 2022 | | 2022 |
| An In Vivo CRISPR Screening Platform to Identify New Therapeutic Targets in AML S Lin, C Larrue, NK Scheidegger, BKA Seong, NV Dharia, C Wechsler, ... Blood 138, 266, 2021 | | 2021 |
| Detection of VNN2 Surface Expression Defines a Subgroup in Acute Lymphoblastic Leukemia with a High Risk of Relapse NK Scheidegger Universität Zürich, 2015 | | 2015 |
| Xenografts of Highly Resistant Leukemia Recapitulate the Clonal Composition of the Leukemogenic Compartment N Scheidegger Univ. Zürich, 2012 | | 2012 |
| Leukemia initiating cells are frequent and oligoclonal in de novo resistant ALL B Bornhauser, M Schmitz, P Breithaupt, N Scheidegger, P Mirkowska, ... Cancer Research 71 (8_Supplement), 5330-5330, 2011 | | 2011 |
| LEUCÉMIES AIGUËS DE L’ENFANT–QUOI DE NEUF? N Bodmer, N Scheidegger, TR Schlaepfer | | |
| Mitochondrial Fusion Supports Proliferation of Leukemia-Initiating Cells Through mTORC1 in Patient-Derived Xenograft Models C Larrue, S Mouche, S Lin, F Simonetta, N Scheidegger, L Poulain, ... Available at SSRN 4114955, 0 | | |
